Angiogenesis and the role of epigenetics in metastasis

Clinical and Experimental Metastasis

Volumn 20, Issue 3, 2003, Pages 215-227

  Coomber, Brenda L ^a   Yu, Joanne L ^b   Fathers, Kelly E ^a   Plumb, Claire ^a   Rak, Janusz W ^b  

^a UNIVERSITY OF GUELPH   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Epigenetic; Microenvironment; Microvasculature; Tumor progression

Indexed keywords

ANGIOGENESIS INHIBITOR; GROWTH FACTOR; SEMAXANIB;

ANGIOGENESIS; CANCER CELL; CANCER GROWTH; GENE EXPRESSION; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC STABILITY; GENOME; HYPOXIA; INFLAMMATION; METASTASIS; ONCOGENE; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANGIOGENESIS INHIBITORS; ANIMALS; GROWTH SUBSTANCES; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0242500847     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022935117193     Document Type: Review

References (168)

1. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185-8.
2. Hellmann K. Antimetastatic drugs: Laboratory to clinic. Clin Exp Metastasis 1984; 2: 1-4.
3. Liotta LA. Clinical applications of anti-invasion and anti-metastatic agents. Prog Clin Biol Res 1986. 212; 183-95.
4. Fidler IJ. Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1990; 50: 6130-8.
5. Chambers AF, MacDonald IC, Schmidt EE et al. Clinical targets for anti-metastasis therapy. Adv Cancer Res 2000; 79: 91-121.
6. Arbiser JL, Moses MA, Fernandez CA et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 1997; 94: 861-6.
7. Naumov GN, MacDonald IC, Chambers AF et al. Solitary cancer cells as a possible source of tumor dormancy? Semin Cancer Biol 2001; 11: 271-6.
8. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-63.
9. Fidler IJ. Selection of successive cell lines for metastasis. Nature. 1973. 242: 148-9.
10. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977; 197: 893-5.
11. Morikawa K, Walker SM, Nakajima M et al. Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 1988; 48: 6863-71.
12. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 1: 571-3.
13. Kerbel RS. Growth dominance of the metastatic cancer cell: Cellular and molecular aspects. Adv Cancer Res 1990; 55: 87-132.
14. Waghorne C, Korczak B, Breitman ML et al. Analysis of growth, selection, and metastasis of tumor cell populations in vivo using random insertions of foreign DNA as genetic tags. In Prodi G (ed): Cancer Metastasis, Biological and Biochemical Mechanisms and Clinical Aspects. New York: Plenum Press 1988; 27-38.
15. Fearon ER, Vogelstein B/A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
16. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-8.
17. Hart IR, Easty D. Identification of genes controlling metastatic behaviour. Br J Cancer 1991; 63: 9-12.
18. Steeg PS. Molecular biology of breast cancer metastasis. 'Has it spread?': Disarming one of the most terrifying questions. Breast Cancer Res 2000; 2: 396-9.
19. Lopez T, Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2002; 1: 339-53.
20. Clark EA, Golub TR, Lander ES et al. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406: 532-5.
21. Oft M, Akhurst RJ, Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 2002; 4: 487-94.
22. Chambers AF, Naumov GN, Vantyghem SA et al. Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Res 2000; 2: 400-7.
23. Fidler IJ. The relationship of embolic homogeneity, number, size, and viability to the incidence of experimental metastasis. Eur J Cancer 1973; 9: 223-7.
24. Miller FR, Heppner GH. Cellular interactions in metastasis. Cancer Metastasis Rev 1990; 9: 21-34.
25. Heppner GH, Miller BE. Therapeutic implications of tumor heterogeneity. Semin Oncol 1989; 16: 91-105.
26. Heppner GH. Tumor cell societies. J Natl Canc Inst 1989; 81: 648-9.
27. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375-9.
28. Rak J. Possible role of tumour stem-end cell interaction in metastasis. Med Hypoth 1989; 29: 17-9.
29. Wojtukiewicz MZ, Sierko E, Klement P et al. The hemostatic system and angiogenesis in malignancy. Neoplasia 2001; 3: 371-84.
30. Barcellos-Hoff M-H. It takes a tissue to make a tumor: Epigenetics, cancer and the microenvironment. J Mamm Gland Biol Neoplasia 2001; 6: 213-21.
31. Barcellos-Hoff M-H, Brooks AL. Extracellular signaling through microenvironment: A hypothesis relating carcinogenesis, bystander effects, and genomic instability. Radiation Research 2001; 156: 618-27.
32. Chang GW, Terzaghi-Howe M. Multiple changes in gene expression are associated with normal cell-induced modulation of the neoplastic phenotype. Cancer Res 1998; 58: 4445-52.
33. Bauer G. Elimination of transformed cells by normal cells: A novel concept for the control of carcinogenesis. Histol Histopathol 1996; 11: 237-55.
34. Webb CP, Vande WG. Genes that regulate metastasis and angiogenesis. J Neurooncol 2000; 50: 71-87.
35. Xu J, Rodriguez D, Petitclerc E. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001; 154: 1069-79.
36. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275: 1521-4.
37. O'Reilly MS, Pirie-Shepherd S, Lane WS et al. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999; 285: 1926-8.
38. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
39. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
40. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002; 1: 219-27.
41. Rak J, St. Croix B, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anti-Cancer Drugs 1995; 6: 3-18.
42. Rak J, Kerbel RS. Oncogenes and tumor angiogenesis. In Rak J (ed): Oncogene-Directed Therapies. Totowa, New Jersey: Humana Press 2002.
43. Rak J, Filmus J, Kerbel RS. Reciprocal paracrine interactions between tumor cells and endothelial cells. The 'angiogenesis progression' hypothesis. Eur J Cancer 1996; 32A: 2438-50.
44. Skobe M, Rockwell P, Goldstein N et al. Halting angiogenesis suppresses carcinoma cell invasion. Nature Med 1997; 3: 1222-7.
45. Brooks PC, Stromblad S, Klemke R et al. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-22.
46. Gershenwald JE, Fidler IJ. Targeting lymphatic metastasis. Science 2002; 296: 1811-2.
47. Hamada J, Cavanaugh PG, Miki K et al. A paracrine migration-stimulating factor for metastatic tumor cells secreted by mouse hepatic sinusoidal endothelial cells: Identification as complement component C3b. Cancer Res 1993; 53: 4418-23.
48. Nicosia RF, Tchao R, Leighton J. Angiogenesis-dependent tumor spread in reinforced fibrin clot culture. Cancer Res 1983; 43: 2159-66.
49. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
50. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995; 1: 149-53.
51. Bell CW, Pathak S, Frost P. Unknown primary tumors: Establishment of cell lines, identification of chromosomal abnormalities, and implications for a second type of tumor progression. Cancer Res 1989; 49: 4311-5.
52. Folkman J. Angiogenesis-dependent diseases. Semin Oncol 2001; 28: 536-42.
53. Rak JW, Hegmann EJ, Lu C et al. Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. J Cell Physiol 1994; 159: 245-55.
54. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
55. Holash J, Maisonpierre PC, Compton D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-8.
56. Yancopoulos GD, Davis S, Gale NW et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
57. Pettersson A, Nagy JA, Brown LF et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 2000; 80: 99-115.
58. Maniotis AJ, Folberg R, Hess A et al. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am J Pathol 1999; 155: 739-52.
59. Rak J, Kerbel RS. Prospects and progress in the development of anti-angiogenic agents. In Rosenberg SA (ed): Principles and Practice of Biologic Therapy of Cancer - Updates. New York: Lippincott, Williams & Wilkins 2002; 3: 1-13.
60. Rak J, Yu JL, Klement G et al. Oncogenes and angiogenesis: Signaling three-dimensional tumor growth. J Invest Dermatol Symp Proc 2000; 5: 24-33.
61. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996; 69: 135-74.
62. Lyden D, Young AZ, Zagzag D et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999; 401: 670-7.
63. Rohan RM, Fernandez A, Udagawa T et al. Genetic heterogeneity of angiogenesis in mice. FASEB J 2000; 14: 871-6.
64. Harris AL. Hypoxia - a key regulatory factor in turnout growth. Nat Rev Cancer 2002; 2: 38-47.
65. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000; 35: 71-103.
66. Jain RK, Safabakhsh N, Sckell A et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998; 95: 10820-5.
67. Dameron KM, Volpert OV, Tainsky MA et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
68. Rak J, Mitsuhashi Y, Bayko L et al. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575-80.
69. Grugel S, Finkenzeller G, Weindel K et al. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995; 270: 25915-9.
70. Mazure NM, Chen EY, Yeh P et al. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 1996; 56: 3436-40.
71. Laderoute KR, Alarcon RM, Brody MD et al. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin Cancer Res 2000; 6: 2941-50.
72. Cohen T, Nahari D, Cerem LW et al. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996; 271: 736-41.
73. Koura AN, Liu W, Kitadai Y et al. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density. Cancer Res 1996; 56: 3891-4.
74. Rak J, Mitsuhashi Y, Sheehan C et al. Oncogenes and tumor anglogenesis: differential modes of vascular endothelial growth factor upregulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 2000; 60: 490-8.
75. Sheta EA, Harding MA, Conaway MR et al. Focal adhesion kinase, Rap1, and transcriptional induction of vascular endothelial growth factor. J Natl Cancer Inst 2000; 92: 1065-73.
76. Weidner N, Semple JP, Welch WR et al. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
77. Gasparini G, Toi M, Gion M et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89: 139-47.
78. Toi M, Inada K, Hoshima S et al. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1995; 1: 961-4.
79. Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-9.
80. Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997; 57: 3924-8.
81. Filleur S, Volpert OV, Degeorges A et al. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev 2001; 15: 1373-82.
82. Fidler IJ. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst 2001; 93: 1040-1.
83. Fidler IJ, Yano S, Zhang RD et al. The seed and soil hypothesis: Vascularization and brain metastases. Lancet Oncol 2002; 3: 53-7.
84. McCarthy M. Targeted drugs take center stage at US cancer meeting. Lancet 2001; 357: 1593.
85. Coussens LM, Raymond WW, Bergers G et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13: 1382-97.
86. Rak J, Mitsuhashi Y, Sheehan C et al. Collateral expression of proangiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikis. Neoplasia 1999; 1: 23-30.
87. Frisch SM, Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol 1997; 9: 701-6.
88. Rak J, Mitsuhashi Y, Erdos V et al. Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: Suppression by expression of a mutant c-H-ras oncogene. J Cell Biol 1995; 131: 1587-98.
89. Rosen K, Rak J, Leung T et al. Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells. J Cell Biol 2000; 149: 447-56.
90. Rosen K, Rak J, Jin J et al. Downregulation of Bak plays a critical role in the growth of the ras-induced malignant phenotype in intestinal epithelial cells. Curr Biol 1998; 8: 13314.
91. Graeber TG, Osmanian C, Jacks T et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
92. Yu JL, Rak JW, Carmeliet P et al. Heterogeneous vascular dependence of tumor cell populations. Am J Pathol 2001; 158: 1325-34.
93. Yu JL, Rak JW, Coomber BL et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002; 295: 1526-8.
94. Kondo A, Safaei R, Mishima M et al. Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res 2001; 61: 7603-7.
95. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001; 106: 148-56.
96. Plate KH, Breier G, Welch HA et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845-8.
97. Hill RP, De Jaeger K, Jang A et al. pH, hypoxia and metastasis. Novartis Found Symp 2001; 240: 154-65.
98. Postovit LM, Adams MA, Lash GE et al. Oxygen-mediated regulation of tumour cell invasiveness: involvement of a nitric oxide signalling pathway. J Biol Chem 2002; 277: 35730-7.
99. Luzzi KJ, MacDonald IC, Schmidt EE et al. Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998; 153: 865-73.
100. Cameron MD, Schmidt EE, Kerkvliet N et al. Temporal progression of metastasis in lung: Cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res 2000; 60: 2541-6.
101. Monsky WL, Carreira CM, Tsuzuki Y et al. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: Mammary fat pad versus cranial tumors. Clin Cancer Res 2002; 8: 1008-13.
102. Rak JW, Yu JL, Kerbel RS et al. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors. Cancer Res 2002; 62: 1931-4.
103. Kubens BS, Zanker KS. Differences in migration capacity of primary human colon carcinoma cells (SW480) and their lymph node metastatic derivatives (SW620). Cancer Lett 1998; 131: 55-64.
104. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 24-5.
105. Kitayama J, Tsuno N, Sunami E et al. E-selectin can mediate the arrest type of adhesion of colon cancer cells under physiological shear flow. Eur J Cancer 2000; 36: 121-7.
106. Rice GE, Bevilacqua MP. An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science 1989; 246: 1303-6.
107. Kim YJ, Borsig L, Varki NM et al. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA 1998; 95: 9325-30.
108. Cheresh DA. Structure, function and biological properties of integrin alpha v beta 3 on human melanoma cells. Cancer Metastasis Rev 1991; 10: 3-10.
109. Lafernie RM, Buchanan MR, Orr FW. Adhesion molecules and their role in cancer metastasis. Cell Biophys 1993; 23: 3-89.
110. Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 1999; 18: 345-57.
111. Brundell S, Ellis T, Dodd T et al. Hematogenous spread as a mechanism for the generation of abdominal wound metastases following laparoscopy. Surg Endosc 2002; 16: 292-5.
112. Heppner GH. Tumor heterogeneity. Cancer Res 1989; 44: 2259-65.
113. Rofstad EK, Rasmussen H, Galappathi K et al. Hypoxia promotes lymph node metastasis in human melanoma xenografts by upregulating the urokinase-type plasminogen activator receptor. Cancer Res 2002; 62: 1847-53.
114. Dachs GU, Patterson AV, Firth JD et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997; 3: 515-20.
115. Dachs GU, Tozer GM. Hypoxia modulated gene expression: Angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000; 36: 1649-60.
116. Denko N, Schindler C, Koong A et al. Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. Clin Cancer Res 2000; 6: 480-7.
117. Sanchez-Cespedes M, Esteller M, Wu L et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000; 60: 892-5.
118. Tang X, Khuri FR, Lee JJ et al. Hypermethylation of the death associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 2000; 92: 1511-16.
119. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998; 153: 333-9.
120. Hirohashi S. Molecular aspects of adhesion-epigenetic mechanism for inactivation of the E-cadherin-mediated cell adhesion system in cancer. Verh Dtsch Ges Pathol 2000; 84: 28-32.
121. Park TJ, Han SU, Cho YK et al. Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer 2001; 92: 2760-8.
122. Graff JR, Gabrielson E, Fuji H et al. Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 2000; 275: 2727-32.
123. Swartz MA, Skobe M. Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc Res Tech 2001; 55: 92-9.
124. Padera TP, Kadambi A, di Tomaso E et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002; 296: 1883-6.
125. Stacker SA, Caesar C, Baldwin ME et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-91.
126. Pepper MS. Lymphangiogenesis and tumor metastasis: Myth or reality? Clin Cancer Res 2001; 7: 462-8.
127. Skobe M, Hawighorst T, Jackson DG et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192-8.
128. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000; 19: 5598-605.
129. Mandriota SJ, Jussila L, Jeltsch M et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001; 20: 672-68.
130. Amioka T, Kitadai Y, Tanaka S et al. Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur J Cancer 2002; 38: 1413-9.
131. Cao Y, Linden P, Farnebo J et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA 1998; 95: 14389-94.
132. Skobe M, Hamberg LM, Hawighorst T et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001; 159: 893-903.
133. Folkman J, Hahnfeldt P, Hlatky L. Cancer: Looking outside the genome. Nat Rev Mol Cell Biol 2000; 1: 76-9.
134. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 1991; 13: 31-6.
135. Kerbel RS. A cancer therapy resistant to resistance. Nature 1997; 390: 335-6.
136. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990; 9: 253-66.
137. Hanahau D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
138. Parangi S, O'Reilly MS, Christofori G et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 1996; 93: 2002-7.
139. D'Amore P. Antiangiogenesis as a strategy for antimetastasis. Seminars Thromb Hemostasis 1988; 14: 73-8.
140. Kuenen BC, Rosen L, Smit EF et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002; 20: 1657-67.
141. Tran J, Master Z, Yu JL et al. Induction of endothelial cell resistance to chemotherapy by VEGF mediated up-regulation of survivin. Proc Natl Acad Sci USA 2002; 99: 4349-54.
142. Kerbel RS, Yu J. Tran J et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001; 20: 79-86.
143. Dong Z, Radinsky R, Fan D et al. Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. J Natl Cancer Inst 1994; 86: 913-20.
144. Karpanen T, Egeblad M, Karkkainen MJ et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001; 61: 1786-90.
145. He Y, Kozaki K, Karpanen T et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002; 94: 785-7.
146. Brekken RA, Thorpe PE. Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res 2001; 21: 4221-9.
147. Lin P, Buxton JA, Acheson A. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 1998; 95: 8829-34.
148. Folkman J, Browder T, Palmblad J. Angiogenesis research: Guidelines for translation to clinical application. Thromb Haemost 2001; 86: 23-33.
149. Dameron KM, Volpert OV, Tainsky MA et al. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb Symp Quant Biol 1994; 59: 483-9.
150. Giaccia A. Genetic basis of altered responsiveness of cancer cells to their microenvironment. In Rak J (ed): Oncogene-Directed Therapies. Totowa, New Jersey: Humana Press 2002; 1-34.
151. Tullo A, D'Erchia AM, Honda K et al. Characterization of p53 mutations in colorectal liver metastases and correlation with clinical parameters. Clin Cancer Res 1999; 5: 3523-8.
152. Giannelli G, Fransvea E, Marinosci F et al. Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3 beta1 integrin. Am J Pathol 2002; 161: 183-93.
153. Barshishat M, Ariel A, Cahalon L et al. TNF alpha and IL-8 regulate the expression and function of CD44 variant proteins in human colon carcinoma cells. Clin Exp Metastasis 2002; 19: 327-37.
154. Wu Y, Dakar S, Sao L et al. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 2002; 62: 1030-5.
155. Rofstad EK, Halsor EF. Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: Involvement of microvascular hot spots induced in hypoxic foci by Interleukin 8. Br J Cancer 2002; 86: 301-8.
156. Rofstad EK, Rasmussen H, Galappathi K et al. Hypoxia promotes lymph node metastasis in human melanoma xenografts by upregulating the urokinase-type plasminogen activator receptor. Cancer Res 2002; 62: 1847-53.
157. Kozaki K, Koshikawa K, Tatematsu Y et al. Multi-faceted analyses of a highly metastatic human lung cancer cell line NC1-H460-LNM35 suggest mimicry of inflammatory cells in metastasis. Oncogene 2001; 20: 4228-34.
158. Pilch J, Habermann R, Felding-Habermann B. Unique ability of integrin alpha(v)beta 3 to support tumor cell arrest under dynamic flow conditions. J Biol Chem 2002; 277: 21930-8.
159. Kitayama J, Nagawa H, Tsuno N et al. Laminin mediates tethering and spreading of colon cancer cells in physiological shear flow. Br J Cancer 1999; 80: 1927-34.
160. Schagdarsurengin U, Gimm O, Hoang-Vu C et al. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res 2002; 62: 3698-701.
161. Li LC, Zhao H, Nakajima K et al. Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. J Urol 2001; 166: 705-9.
162. Domann FE, Rice JC, Hendrix MJ et al. Epigenetic silencing of maspin gene expression in human breast cancers. Int J Cancer 2000; 85: 805-10.
163. Bachman KE, Herman JG, Corn PG et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999; 59: 798-802.
164. Tulchinsky E, Grigorian M, Tkatch T et al. Transcriptional regulation of the mts1 gene in human lymphoma cells: the role of DNA-methylation. Biochim Biophys Acta 1995; 1261: 243-8.
165. Potter E, Braun S, Lehmann U et al. Molecular cloning of a functional promoter of the human plakoglobin gene. Eur J Endocrinol 2001: 145: 625-33.
166. Chen LM, Chai KX. Prostasin serine protease inhibits breast cancer invasiveness and is transcriptionally regulated by promoter DNA methylation. Int J Cancer 2002; 97: 323-9.
167. Tamada H, Kitazawa R, Gohji K et al. Epigenetic regulation of human bone morphogenetic protein 6 gene expression in prostate cancer. J Bone Miner Res 2001; 16: 487-96.
168. Lu A, Gupta A, Li C et al. Molecular mechanisms for aberrant expression of the human breast cancer specific gene 1 in breast cancer cells: Control of transcription by DNA methylation and intronic sequences. Oncogene 2001; 20: 5173-5185.